Ribociclib added to endocrine therapy extends survival in postmenopausal metastatic breast cancer patients

Menin inhibitors emerge as new treatment for advanced AML

The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.

November 22, 2024

Vol.50 No.44

By Ghayas Issa

Clinical Roundup

Hemokine modulatory regimen shows promise for TNBC in phase I study

A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase I clinical trial for patients with triple-negative breast cancer, the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.

November 22, 2024

Vol.50 No.44

Drugs & Targets

FDA approves new alternative standard related to mammography report assessments

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”

November 22, 2024

Vol.50 No.44

Clinical

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline

New data indicate that, professional guidelines notwithstanding, doctors rarely address concerns about sexual health when they treat women with cancer.

November 15, 2024

Vol.50 No.43

By Claire Marie Porter

In Brief

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.

November 15, 2024

Vol.50 No.43

Ribociclib added to endocrine therapy extends survival in postmenopausal metastatic breast cancer patients

YOU MAY BE INTERESTED IN

Menin inhibitors emerge as new treatment for advanced AML

Hemokine modulatory regimen shows promise for TNBC in phase I study

FDA approves new alternative standard related to mammography report assessments

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

Renew today!

Subscriber content

Never miss an issue!

Login

Ribociclib added to endocrine therapy extends survival in postmenopausal metastatic breast cancer patients

YOU MAY BE INTERESTED IN

Menin inhibitors emerge as new treatment for advanced AML

Hemokine modulatory regimen shows promise for TNBC in phase I study

FDA approves new alternative standard related to mammography report assessments

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancerData indicate low adherence to ASCO guideline

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

Never miss an issue!

Login

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline